Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2024-05-05 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
WHO selects proposed INN for ATL1102 3 pages 115.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Percheron Therapeutics Limited regarding the selection of a proposed International Nonproprietary Name (INN) for their drug candidate ATL1102. It discusses regulatory milestones, naming conventions, and next steps for the drug development. The content is a corporate announcement about a regulatory naming milestone rather than a financial report, earnings release, management discussion, or any other detailed financial or governance report. It does not contain financial statements, audit information, or shareholder voting results. The document is a formal announcement of a regulatory milestone and does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory update. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-05-05 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 411.7KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Activities Report and Appendix 4C' for the quarter ended 31 March 2024. It provides a detailed update on the company's clinical trial progress, investor engagement activities, financial position including cash flow statements, and payments to related parties. The inclusion of the Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document contains substantive financial data and analysis for the quarter, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-04-29 English
Change in substantial holding 6 pages 233.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder filed under the Corporations Act 2001 Section 671B. It details changes in voting power and shareholdings of Platinum Investment Management Limited in Percheron Therapeutics Limited, including dates, number of shares disposed, and voting power percentages. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it is not a financial report or other type of filing. Therefore, the correct classification is MRQ.
2024-04-25 English
ATL1102 Clinical Trial Update 2 pages 261.8KB
Regulatory Filings Classification · 95% confidence The document is a clinical trial update from Percheron Therapeutics Limited, providing progress details on patient recruitment and study phases for a phase IIb clinical trial. It contains no financial data, no regulatory form references, no voting or management changes, and no financial results. The document is an operational update on clinical trial progress, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is also not a regulatory filing or legal proceeding. Given the nature of the content, it is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous announcements that do not fit other specific categories.
2024-04-01 English
ATL1102 Data presented at MDA Annual Conference 6 pages 2.2MB
Investor Presentation Classification · 95% confidence The document is a detailed announcement and presentation of scientific data related to Percheron Therapeutics Limited's ATL1102 drug, focusing on muscular dystrophy research. It includes summaries of poster presentations at the Muscular Dystrophy Association Annual Scientific Conference, detailed clinical trial data from a Phase 2a study, preclinical research in mice, and plans for a Phase 2b study. The content is scientific and research-focused, presenting clinical trial results, proteomics analysis, and biological mechanisms. It is not a financial report, earnings release, regulatory filing, or management discussion. It is also not a proxy, voting result, or capital structure announcement. The document is a presentation of scientific and clinical data at a conference, intended for researchers, clinicians, partners, and investors. This fits the definition of an Investor Presentation (IP), as it provides detailed information on the company's drug development, clinical trial progress, and scientific findings relevant to investors and stakeholders. The document length (15,000 characters) and detailed content confirm it is a full presentation, not just an announcement or summary.
2024-03-03 English
Half Yearly Report and Accounts 24 pages 9.8MB
Interim / Quarterly Report Classification · 100% confidence The document is titled as an 'Interim Financial Report for the half-year ended 31 December 2023' for Percheron Therapeutics Limited. It contains detailed financial statements including the statement of profit or loss, statement of financial position, cash flows, notes to the financial statements, directors' report, and an auditor's review report. The reporting period is explicitly stated as a half-year period ending 31 December 2023. The content includes comprehensive financial data and analysis for this interim period, not just an announcement or summary. The presence of an auditor's review report further confirms this is a formal interim financial report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2024-02-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.